PALO ALTO, Calif.--(BUSINESS WIRE)--Dec 28, 2022--

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 41 st Annual J.P. Morgan Healthcare Conference.

Guardant Health’s management is scheduled to present and participate in a Q&A session on Monday, January 9 th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360 ®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI ® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

View source version on businesswire.com:https://www.businesswire.com/news/home/20221228005079/en/

CONTACT: Investor Contact:

Alex Kleban

investors@guardanthealth.com

+1 657-254-5417Media Contact:

Michele Rest

press@guardanthealth.com

+1 215-910-2138

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH SCIENCE RESEARCH HEALTH TECHNOLOGY ONCOLOGY

SOURCE: Guardant Health, Inc.

Copyright Business Wire 2022.

PUB: 12/28/2022 08:00 AM/DISC: 12/28/2022 08:01 AM

http://www.businesswire.com/news/home/20221228005079/en